Photo of Thomas Powles taken from X/Twitter
Feb 1, 2024, 15:42
Thomas Powles: Enfortumab Vedotin and Pembrolizumab shows broad spectrum of activity for Regional Recurrence, Progression-free survival and Overall Survival in all subgroups
Thomas Powles, Director of Barts Cancer Centre, shared a post on X/Twitter:
“Enfortumab, Vedotin and Pembrolizumab shows broad spectrum of activity for Regional Recurrence (RR), Progression-free survival (PFS) and Overall Survival (OS) in all subgroups. This includes subsets such as lymph node disease, liver metastasis, PD-L1 status, upper tract disease, and platinum eligibility. This positive data underlines Enfortumab Vedotin and Pembrolizumab as a new standard of care.”
Source: Thomas Powles/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19